Our group attempts to unravel the molecular bases of primary immunodeficiencies (PIDs), a large group of rare conditions (more that 350 types described so far) that virtually affect any cell type of the immune system and increase the risk of infections, autoimmunity and cancer in patients. We take a multidisciplinary clinical, anatomic, genetic, epigenetic and functional approach. By correlating clinical and experimental data, we aim to achieve a better understanding of these rare diseases and lay the grounds for, repurposed or new, more effective treatments.

• To define the anatomical, cellular, molecular and (epi)genetic bases of immunological dysfunction in patients diagnosed with primary immunodeficiency in our clinic.
• The maturation and functional specialization of human B lymphocytes, and its pathophysiology in primary and secondary antibody immunodeficiencies.
• The analysis of the immunological reconstitution after haemopoietic stem cell transplantation, and the discovery and clinical validation of immunological biomarkers for immunosuppression and tolerance in solid organ transplantation.
• The development and clinical implementation of patient-tailored monitoring schemes of immunotherapies in wide clinical use.